An amylin analog used as a challenge test for Alzheimer's disease. Issue 1 (21st January 2017)

• Record Type: Journal Article
• Authors: Zhu, Haihao; Stern, Robert A.; Tao, Qiushan; Bourlas, Alexandra; Essis, Maritza D.; Chivukula, Meenakshi; Rosenzweig, James; Steenkamp, Devin; Xia, Weiming; Mercier, Gustavo A.; Tripodis, Yorghos; Farlow, Martin; Kowall, Neil; Qiu, Wei Qiao
• Is Part Of: Alzheimer's & dementia. Volume 3:Issue 1(2017)
• Page Start: 33
• Page End: 43
• Publication Date: 2017-01-21
• Subjects: Alzheimer's disease (AD) -- Amylin challenge -- Pramlintide -- Safety -- Diagnosis -- Biomarkers; Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1016/j.trci.2016.12.002
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: Introduction: Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods: We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results: None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid‐β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol‐binding protein 4, which separates AD subjects from control subjects. Discussion: Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.